161 related articles for article (PubMed ID: 1310887)
1. Clinical and histopathologic evaluation of the expression of Ha-ras and fes oncogene products in lung cancer.
Nishio H; Nakamura S; Horai T; Ikegami H; Matsuda M
Cancer; 1992 Mar; 69(5):1130-6. PubMed ID: 1310887
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of nuclear DNA content and expression of the ras oncogene product in lung cancer.
Miyamoto H; Harada M; Isobe H; Akita HD; Haneda H; Yamaguchi E; Kuzumaki N; Kawakami Y
Cancer Res; 1991 Dec; 51(23 Pt 1):6346-50. PubMed ID: 1657384
[TBL] [Abstract][Full Text] [Related]
3. Incidence of ras oncogene activation in lung carcinomas in Hong Kong.
Lung ML; Wong M; Lam WK; Lau KS; Kwan S; Fu KH; Cheung H; Yew WW
Cancer; 1992 Aug; 70(4):760-3. PubMed ID: 1322782
[TBL] [Abstract][Full Text] [Related]
4. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.
Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H
Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical and immunoblot analyses of ras-p21 expression in lung carcinomas.
Koshiishi Y; Noguchi M; Nakajima T; Hirohashi S; Shimosato Y; Hayata Y
Acta Pathol Jpn; 1989 Oct; 39(10):643-7. PubMed ID: 2686349
[TBL] [Abstract][Full Text] [Related]
6. Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma.
Yanagawa N; Leduc C; Kohler D; Saieg MA; John T; Sykes J; Yoshimoto M; Pintilie M; Squire J; Shepherd FA; Tsao MS
J Thorac Oncol; 2012 Oct; 7(10):1513-21. PubMed ID: 22982652
[TBL] [Abstract][Full Text] [Related]
7. Enhanced expression of c-Ha-ras p21 in human stomach adenocarcinomas defined by immunoassays using monoclonal antibodies and in situ hybridization.
Ohuchi N; Hand PH; Merlo G; Fujita J; Mariani-Costantini R; Thor A; Nose M; Callahan R; Schlom J
Cancer Res; 1987 Mar; 47(5):1413-20. PubMed ID: 2434216
[TBL] [Abstract][Full Text] [Related]
8. Expression of ras p21 and myc p62 oncoproteins in small cell and non small cell carcinoma of the lung.
Spandidos DA; Zakinthinos S; Petraki C; Sotsiou F; Yiagnisis M; Dimopoulos AM; Roussos C; Field JK
Anticancer Res; 1990; 10(5A):1105-14. PubMed ID: 2173469
[TBL] [Abstract][Full Text] [Related]
9. Protein expression profiles of non-small cell lung carcinomas: correlation with histological subtype.
Volm M; Koomägi R; Efferth T; Mattern J
Anticancer Res; 2002; 22(4):2321-4. PubMed ID: 12174921
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of K-ras mutations, ras oncoprotein, and c-erb B-2 oncoprotein expression in adenocarcinoma of the lung.
Nemunaitis J; Klemow S; Tong A; Courtney A; Johnston W; Mack M; Taylor W; Solano M; Stone M; Mallams J; Mues G
Am J Clin Oncol; 1998 Apr; 21(2):155-60. PubMed ID: 9537203
[TBL] [Abstract][Full Text] [Related]
11. Ras p21 protein immunoreactivity and its relationship to p53 expression and prognosis in gallbladder and extrahepatic biliary carcinoma.
Lee CS
Eur J Surg Oncol; 1997 Jun; 23(3):233-7. PubMed ID: 9236898
[TBL] [Abstract][Full Text] [Related]
12. [Clinical significance of oncogene product expression in human lung cancer].
Dosaka-Akita H; Harada M; Miyamoto H; Kawakami Y
Nihon Kyobu Shikkan Gakkai Zasshi; 1992 Aug; 30(8):1441-7. PubMed ID: 1331597
[TBL] [Abstract][Full Text] [Related]
13. Expression pattern of the scaffold protein IQGAP1 in lung cancer.
Nakamura H; Fujita K; Nakagawa H; Kishi F; Takeuchi A; Aute I; Kato H
Oncol Rep; 2005 Mar; 13(3):427-31. PubMed ID: 15706411
[TBL] [Abstract][Full Text] [Related]
14. Frequent mutations of Ki-ras but no mutations of Ha-ras and p53 in lung lesions induced by N-nitrosobis(2-hydroxypropyl)amine in rats.
Kitada H; Tsutsumi M; Tsujiuchi T; Takahama M; Fukuda T; Narita N; Konsihi Y
Mol Carcinog; 1996 Apr; 15(4):276-83. PubMed ID: 8634086
[TBL] [Abstract][Full Text] [Related]
15. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.
Bland KI; Konstadoulakis MM; Vezeridis MP; Wanebo HJ
Ann Surg; 1995 Jun; 221(6):706-18; discussion 718-20. PubMed ID: 7794075
[TBL] [Abstract][Full Text] [Related]
16. Mutation affecting the 12th amino acid of the c-Ha-ras oncogene product occurs infrequently in human cancer.
Feinberg AP; Vogelstein B; Droller MJ; Baylin SB; Nelkin BD
Science; 1983 Jun; 220(4602):1175-7. PubMed ID: 6304875
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous detection of genetic and immunological markers in non-small cell lung cancer: prediction of metastatic potential of tumor.
Zborovskaya I; Gasparian A; Kitaeva M; Polotzky B; Tupitzin N; Machaladze Z; Gerasimov S; Shtutman M; Jakubovskaya M; Davidov M; Tatosyan A
Clin Exp Metastasis; 1996 Nov; 14(6):490-500. PubMed ID: 8970579
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients.
Rosell R; Li S; Skacel Z; Mate JL; Maestre J; Canela M; Tolosa E; Armengol P; Barnadas A; Ariza A
Oncogene; 1993 Sep; 8(9):2407-12. PubMed ID: 8395679
[TBL] [Abstract][Full Text] [Related]
19. Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer.
Huang CL; Taki T; Adachi M; Konishi T; Higashiyama M; Kinoshita M; Hadama T; Miyake M
Int J Oncol; 1998 Mar; 12(3):553-63. PubMed ID: 9472092
[TBL] [Abstract][Full Text] [Related]
20. [Detection of K-ras oncogene activation in human lung cancer and its possible clinical application].
Zhang G; Sun Y; Wang M
Zhonghua Jie He He Hu Xi Za Zhi; 1995 Oct; 18(5):282-4, 317. PubMed ID: 8762479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
